There is no single best treatment for secondary progressive MS (SPMS), because the right approach depends on whether your disease is still “active,” meaning you’re having relapses or new lesions on MRI, or “non-active,” where disability worsens gradually without obvious inflammatory flare-ups. For active SPMS, a small number of disease-modifying therapies have proven effective. For non-active SPMS, treatment focuses heavily on managing symptoms and slowing physical decline through rehabilitation. Most people with SPMS benefit from a combination of both strategies.
Active vs. Non-Active SPMS
This distinction shapes every treatment decision. Active SPMS means you’ve had at least one relapse or new/enlarging lesions on MRI within the past year. Non-active SPMS means disability is progressing without those signs of ongoing inflammation. The classification follows criteria established in 2014, and your neurologist determines it based on your clinical history and imaging.
The distinction matters because nearly all approved disease-modifying drugs target the inflammatory component of MS. If your disease is still producing new inflammation, those drugs have something to work with. If it isn’t, the progression is driven more by slow neurodegeneration, and current medications are far less effective at stopping that process. One large Italian registry study found that active and non-active SPMS patients accumulated disability at similar rates over time, highlighting how much of the progression in SPMS occurs independently of relapses.
Siponimod: The Leading Approved Option
Siponimod (brand name Mayzent) is the most widely discussed disease-modifying therapy specifically approved for active SPMS. It works by trapping certain immune cells in lymph nodes so they can’t reach the brain and spinal cord. In the large Phase 3 EXPAND trial, siponimod reduced the risk of confirmed disability progression at three months by 21% and at six months by 26% compared to placebo. For patients with active SPMS specifically, those numbers were stronger: 31% and 37% reductions.
Siponimod is a daily oral tablet, which many patients prefer over infusions or injections. Before starting, you’ll need a genetic test to check how your body metabolizes the drug, along with baseline heart monitoring, blood work, and an eye exam. The most common side effects include headache, high blood pressure, and liver enzyme elevations.
Other Disease-Modifying Therapies
Several drugs approved for “relapsing forms of MS” can also be used in active SPMS, since active SPMS technically falls under that umbrella. Natalizumab (Tysabri) is one example. It’s a monthly infusion that blocks immune cells from crossing into the brain, and it’s approved for active secondary progressive disease when patients continue to experience relapses. A biosimilar version was approved by the FDA in 2023, which may lower costs over time.
Ocrelizumab (Ocrevus), a twice-yearly infusion that depletes B cells, is approved for primary progressive MS and relapsing MS but is frequently used off-label in SPMS. A two-year prospective study found that ocrelizumab improved average disability scores in both relapsing and secondary progressive patients, with mean scores dropping from 5.2 to 4.6 on the standard disability scale. However, SPMS patients still showed significant brain volume loss: 100% had measurable brain atrophy by the two-year mark, compared to about 31% of relapsing patients. This illustrates a recurring theme in SPMS treatment. Current drugs can reduce inflammatory damage but struggle to halt the neurodegenerative component.
Cladribine, an immune-resetting drug given as short oral courses, has shown some benefit in early or rapidly evolving SPMS. In one study, 62% of treated patients stabilized, 12.5% improved, and relapse rates dropped from 1.25 to 0.42 per year. It’s not a first-line SPMS treatment, but it may be considered when the disease is transitioning from relapsing-remitting to secondary progressive.
Mitoxantrone
Mitoxantrone is an older chemotherapy agent that was once commonly used for worsening SPMS. It’s rarely prescribed today because of serious cardiac risks. The drug carries a strict lifetime dose cap of 120 to 140 mg per square meter of body surface area, and heart function must be evaluated before every infusion and annually after treatment ends. Late side effects including heart failure and secondary cancers limit its usefulness. Most neurologists now reserve it for aggressive cases where other options have failed.
Symptom Management
For many people with SPMS, especially non-active SPMS, day-to-day quality of life depends more on symptom management than on disease-modifying drugs. The symptoms that respond best to treatment include spasticity, fatigue, bladder problems, pain, and depression.
Muscle stiffness and spasms are among the most disabling SPMS symptoms. Medications like baclofen, tizanidine, and cyclobenzaprine can relax tight muscles. For more localized spasticity, Botox injections into specific muscle groups are another option. Fatigue is trickier. Drugs like amantadine, modafinil, and methylphenidate have been used for years, but a recent study found they performed no better than placebo while causing more side effects. Some antidepressants, particularly fluoxetine and bupropion, may help with both fatigue and the depression that commonly accompanies progressive MS. Bladder dysfunction, pain, sexual dysfunction, and sleep problems each have their own treatment options, and addressing them can significantly improve daily functioning.
Rehabilitation and Exercise
Physical rehabilitation is one of the most consistently beneficial interventions for SPMS, yet it’s often underemphasized compared to medications. Structured exercise programs combining aerobic activity, resistance training, and balance work help maintain functional independence and reduce fatigue. Walking, cycling, and swimming all improve cardiovascular fitness and have direct effects on MS-related exhaustion.
Task-oriented therapy, where you practice real-world activities like climbing stairs, getting in and out of a chair, or cooking, is supported across clinical guidelines as a way to regain or maintain lost function. For people with significant walking impairments, robot-assisted gait training has shown promise as a way to maintain mobility that might otherwise be lost. The key is consistency. Regular, structured exercise doesn’t just slow physical decline; it also improves mood, sleep, and cognitive function.
Stem Cell Transplant
Autologous hematopoietic stem cell transplant (aHSCT) is an intensive procedure that essentially reboots the immune system. It involves harvesting your own stem cells, using chemotherapy to destroy the existing immune system, and then reinfusing the stem cells to rebuild it. A meta-analysis found that 68% of MS patients who underwent aHSCT achieved no evidence of disease activity afterward, with an overall survival rate of 94%.
Those numbers come with serious caveats. Transplant-related mortality runs around 4%, and 79% of early complications in one study were tied to the period of severe immune suppression, including infections, fever, and viral reactivation. Late risks include secondary cancers. The procedure works best in younger patients with active inflammatory disease and shorter disease duration. For someone with longstanding, non-active SPMS and significant accumulated disability, the risks generally outweigh the potential benefits. It’s considered mainly for people with aggressive, treatment-resistant disease who still have substantial inflammatory activity.
What’s in the Pipeline
A new class of drugs called BTK inhibitors is generating significant interest because they can cross the blood-brain barrier, something most current MS drugs cannot do effectively. This means they could potentially target the immune activity happening inside the brain itself, which is thought to drive much of the silent progression in SPMS. Fenebrutinib, developed by Genentech, has met its primary endpoint in three Phase 3 trials, including one in primary progressive MS. These drugs work by reducing B cell activation and also regulating brain-resident immune cells called microglia, which have been linked to the neurodegenerative side of MS progression. Several other BTK inhibitors are also in late-stage trials, and results over the next few years could meaningfully change the treatment landscape for progressive MS.